"hypoallergenic" plausibly means "free of ingredients likely to sensitize the skin"

Novick v. Unilever U.S., Inc., 2026 WL 1879145, No. 25cv4804 (EP) (JBC) (D.N.J. Jul. 30, 2026)

The court mostly allows claims that the “hypoallergenic” and “sensitive skin” representations on Unilever’s Dove Sensitive Skin Body Wash are false and misleading because the body wash contains ingredients that are known skin sensitizers that cause allergic reactions under New Jersey, New York, and California law. According to the complaint, “[t]he scientific and regulatory definition of a skin sensitizer is a substance that causes sensitization by skin contact in a substantial number of persons based on human evidence or appropriate animal testing.”  

A skin sensitizer “may elicit an allergic response at concentrations smaller than 0.1% in individuals who are already sensitized to the chemical,” making the “entire product mixture” a skin sensitizer. Allegedly, a “product that is a skin sensitizer is not hypoallergenic and is not suitable for sensitive skin,” although there’s no FDA regulation defining the terms.

“Like similarly situated consumers,” plaintiffs allegedly do “not know the identity of every ingredient” to which their families “are allergic ... [and do] not know [to] which ingredients” they or their families “may develop an allergy,” but the Dove product allegedly contains at least six skin sensitizers in amounts “that can be reasonably expected to induce an allergic response in a significant number of people, and especially so in the [Product’s] intended customer base.” Consumers allegedly expect a product labeled as “hypoallergenic” to contain no skin sensitizers that could elicit an allergic response in sensitized individuals.

Notably, Dove brand Sensitive Skin Body Bar allegedly “contains neither fragrance chemicals nor a ‘hypoallergenic’ representation on its label and packaging,” and Kroger’s “copycat” sensitive skin bodywash—marketed as comparable to Dove’s—declines to claim it is “hypoallergenic” anywhere on its front label.

On standing, plaintiffs properly pled a price premium theory of economic injury. Plaintiffs identified two cheaper comparators: Dove’s own non-hypoallergenic Sensitive Skin Body Bar and the Kroger Copycat explicitly as a “compare to” alternative.  “A store brand marketed as the cheaper equivalent is, almost by definition, a comparable, cheaper product.” Plaintiffs didn’t need to specify the exact value of their economic injury at the pleading stage.

In addition, “hypoallergenic” etc. was plausibly misleading. The court found the relevant state consumer protection laws to apply “substantially the same” standards, though they “diverge in how much a plaintiff must show at the pleading stage”:

At the pleading stage, the NYGBL and the CA Consumer Laws both require allegations that “a significant portion of the general consuming public or of targeted consumers, acting reasonably in the circumstances, could be misled.” But unlike the NYGBL and the CA Consumer Laws, the NJCFA treats “capacity to mislead” as the “prime ingredient” of consumer fraud and does not have the “significant portion” requirement.

Necessarily, a claim that survives under NY/CA misleadingness would survive under NJ law as well.

Unilever alleged that “hypoallergenic” couldn’t mislead anyone because the word is inherently relative and “not an objective guidance about the specific amount of any ingredient in a product.” The prefix “hypo-” means “less than,” not “zero.” The court disagreed that this prevented reasonable consumers from being deceived. Plaintiffs plausibly alleged that:

“hypoallergenic” and “sensitive skin” communicate to reasonable consumers that the Product: (a) is not itself a skin sensitizer; (b) will not cause irritation, corrosion, or contact dermatitis when used as directed by intended users; (c) does not contain significant amounts of ingredients known to cause such reactions in intended users; and (d) does not contain sensitizers in amounts reasonably expected to induce allergic responses in significant numbers of intended users or sensitized individuals.

That the FDA has declined to define “hypoallergenic” and lets companies decide its meaning was not dispositive. “Unilever’s authorities do not coalesce around a common definition of ‘hypoallergenic.’ That is the hallmark of an ambiguous term—not a settled one.” The court declined to decide on a meaning at this stage.

In addition, “labeling could also be ambiguous if consumers would not understand the label’s representations at face value.” This is the newly emerging consumer protection law meaning of ambiguity: “[A product’s] front label is not ambiguous simply because it is susceptible to two possible meanings; a front label is ambiguous when reasonable consumers would necessarily require more information before reasonably concluding that the label is making a particular representation” (emphasis added). This is the ambiguity “that governs whether a court may look past the front label to the back. The front label here makes a definite representation that the Product is suited for sensitive skin and, as hypoallergenic, will not provoke the reactions that non-hypoallergenic products may.”

The complaint also sufficiently pled that this was in fact misleading. It identified a recognized scientific and regulatory threshold—0.1%—above which a sensitizing ingredient is classified as a skin sensitizer. Citing Unilever’s own Safety Data Sheet, it alleged that the product contains cocamidopropyl betaine, the American Contact Dermatitis Society’s “Allergen of the Year” in 2004, at a concentration of 1 to 10%. Plaintiffs also alleged the presence of five other skin sensitizers, including fragrance chemicals, which are allegedly a leading cause of allergic contact dermatitis according to the American Academy of Dermatology. Other ingredients—citric acid, glycerin, and sodium benzoate—were allegedly recognized or classified as skin sensitizers shown to cause allergic reactions on contact, and several were classified as skin and eye irritants.

Plaintiffs didn’t need to allege laboratory testing under these circumstances, including that the product was “a mass-produced, fixed-formula body wash.”

The presence of Amazon consumer reviews reporting reactions also mattered, though the court considered them not for their truth or as evidence of how the public understands the term “hypoallergenic.”  Although 87% of reviews submitted by Unilever gave the product five stars, that proved little. “That most buyers are satisfied does not establish, as a matter of law, that the label does not mislead people with sensitive skin—the actual consumers whom the ‘significant portion of ... targeted consumers’ standard exists to protect. Consumer fraud could still be plausible despite high product satisfaction” (citing Lanham Act cases accepting 15% and lower confusion).

Nor did the back label, even if consulted, cure the front’s alleged misrepresentation. Here, “reasonable consumers would not require more information before reasonably concluding that the front label [of the Product] was making a specific representation.” “And importantly, requiring a consumer to know the ‘properties, origins, and effects on the skin’ of each listed ingredient in the Product’s back label is ‘plainly untenable.’” The court believed that each of the relevant jurisdictions would so hold (as do I).

Nor were plaintiffs required to allege that they suffered allergic reactions as a result; that wasn’t their theory of deception/harm.

The court then kicked out NJCFA omission claims, but not NJCFA affirmative misrepresentation claims. “To establish an act of omission under the NJCFA, ‘plaintiff must show that defendant (1) knowingly concealed (2) a material fact (3) with the intention that plaintiff rely upon the concealment.’ ” Intent can be alleged generally but must still be plausible.

Plaintiffs alleged that Unilever had knowledge because of: (1) Unilever’s website; (2) the Product’s Safety Data Sheet; and (3) negative reviews posted to the “Dove store” on Amazon. While Unilever’s website acknowledges that “a selection of ingredients used in fragrances have the potential to cause skin allergies in some individuals,” it explains that Unilever discloses its fragrance ingredients “for transparency and to help you make informed choices.” “That statement is candor, not knowledge of falsity or concealment.”

Likewise, the Safety Data Sheet’s statement about chemical concentration was not knowledge of its alleged falsity. “A manufacturer that reasonably reads ‘hypoallergenic’ to mean ‘less’ would not knowingly conceal the alleged misrepresentation by selling the product. And the negative reviews didn’t provide knowledge because plaintiffs never alleged that “Unilever operates the Dove store, monitors Amazon, or receives notice of those reviews.” More generally, “Internet postings, standing alone, do not impute knowledge to the manufacturer without facts indicating that the manufacturer ‘viewed or would have viewed those websites’ or ‘monitored third-party website complaints.’” Pleading monitoring or reporting lines, cy contrast, can support an inference of knowledge.

New York statutory claims survived. California UCL & FAL claims failed, though a CLRA claim survived, because the remedies for the first two are equitable and plaintiffs didn’t plead that they lacked an adequate remedy at law.

The implied warranty claim survived in California and New Jersey; even though it could clean the skin, it was plausibly unfit for ordinary use because it couldn’t be used for the “purpose of being a body wash suitable for sensitive skin,” which was the purpose for which it was sold. After all, just “because a car can be driven does not mean it is merchantable.” Express warranty claims survived in all jurisdictions.

Unjust enrichment survived, but not common-law fraud and fraudulent concealment, given the failings on scienter above.